ReviewOncology research2026
Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Integrative single-cell and spatial transcriptomics analysis reveals a baicalein-responsive 10-gene signature for non-small cell lung cancer.Translational oncology · 2026Article
- The neuroimmune axis in breast cancer: from mechanistic insights to clinical applications.BMC medicine · 2026Review
- Integrative machine learning and single-cell analysis identifies nicotine-related diagnostic genes and myeloid remodeling in COPD.Frontiers in immunology · 2026Article
- Integrated single-cell and spatial transcriptomic analyses identify TRIP6 as a prognostic and EMT-associated biomarker in colorectal cancer.Frontiers in cell and developmental biology · 2026Article
- Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma.Stem cells international · 2026Article
- Destabilization of hsa_circ_0015508 by YTHDF2 Enhances miR-496-Mediated FOXN3 Suppression to Drive Nasopharyngeal Carcinoma Progression.Oncology research · 2026Article
- Circular RNAs in cervical cancer: from ceRNA networks to epitranscriptomic regulation, immune modulation, and metastatic reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor metabolic reprogramming is a core hallmark of cancer, characterized by pathways such as aerobic glycolysis, aberrant lipid metabolism, and glutaminolysis that support rapid proliferation and immunosuppressive microenvironments. Circular RNAs (circRNAs) are highly stable, evolutionarily conserved non-coding RNAs that have emerged as critical modulators of these metabolic shifts. This review aims to systematically elucidate the roles and mechanisms of circRNAs in reprogramming tumor metabolism, and to discuss their clinical potential as biomarkers and therapeutic targets. Through mechanisms including miRNA sponging, protein interactions, regulation of mitochondrial dynamics, and modulation of metabolic enzymes, circRNAs influence key metabolic pathways by targeting glycolytic enzymes, lipid synthesis regulators, and glutaminolysis-related molecules to either facilitate or inhibit their expression. This review systematically summarizes the unique contributions of circRNAs to tumor metabolic reprogramming, highlighting key mechanisms such as regulation of peptide-encoding protein translation, mitochondrial localization function, gene promoter-targeted transcriptional regulation, and cross-pathway metabolic mediation, which underscore their distinct biological advantages and regulatory roles in tumor metabolism. The stability and tissue specificity of circRNAs make them promising diagnostic biomarkers, while their role in drug resistance mediated by metabolic reprogramming highlights their potential as therapeutic targets. Strategies such as circRNA inhibitors, mimics, and nanoparticle-based delivery systems are being explored to modulate tumor metabolism. Despite challenges including complex regulatory networks and limited manipulation tools, advances in high-throughput technologies and clinical trials hold promise for translating circRNA research into novel cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.